3 Prescription Brand, Surface Treatment Firm and Milk Products Stocks With a Strong Future Roadmap: Mankind Pharma, Grauer & Weil (India) and Heritage Foods

Mankind Pharma Rs 2,275.50, P/E 47.91. Grauer & Weil Rs 78.83, P/E 22.12. Heritage Foods Rs 405.40, P/E 26.48. Closing prices of 14 Oct 2026.

Updated: 19 Oct 2026 • 2:42 pm

Posted by:

Quick Answer

Prescription brand, surface treatment firm and milk products stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Grauer & Weil in surface treatment chemicals and related industrial products and Heritage Foods in milk, curd and value-added dairy products sold across southern and other states. FY26 revenue growth was 14.8% at Mankind Pharma, 5.1% at Grauer & Weil and 9.3% at Heritage Foods. P/E stands at 47.91 for Mankind Pharma (industry 37.59), 22.12 for Grauer & Weil (industry 36.60) and 26.48 for Heritage Foods (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Prescription brand, surface treatment firm and milk products stocks give investors exposure to medicines, industrial chemicals and dairy bought every day. Volumes, pricing and margins decide how much of that demand turns into profit.

This list covers three prescription brand, surface treatment firm and milk products stocks: Mankind Pharma for branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Grauer & Weil (India) for surface treatment chemicals and related industrial products and Heritage Foods for milk, curd and value-added dairy products sold across southern and other states. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Prescription Brand, Surface Treatment Firm and Milk Products Stocks?

Prescription brand, surface treatment firm and milk products stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Prescription Brand, Surface Treatment Firm and Milk Products Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three prescription brand, surface treatment firm and milk products stocks as of the 14 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Mankind Pharma	2,275.50	99,065	47.91	37.59	11.74%	0.39
Grauer & Weil (India)	78.83	3,540	22.12	36.60	15.16%	0.01
Heritage Foods	405.40	3,562	26.48	34.85	13.61%	0.33

Among healthcare, chemicals and consumer stocks, Mankind Pharma trades at a premium to the industry P/E, while Grauer & Weil and Heritage Foods trade at a discount.

Why Do Prescription Brand, Surface Treatment Firm and Milk Products Stocks Have a Strong Roadmap in India?

Prescription brand, surface treatment firm and milk products stocks have a strong roadmap in India because prescription demand, manufacturing output and packaged dairy sales keep adding volumes for these firms. Three drivers stand out.

Medicine demand: Doctors prescribe branded formulations across therapies.
Manufacturing output: Factories use surface treatment chemicals.
Dairy demand: Households buy more curd and value-added dairy.

Mankind Pharma: Branded Formulations Anchor the Roadmap

Mankind Pharma's roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.

Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.

Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.

What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.

Grauer & Weil (India): Surface Treatment Chemicals Drive the Pipeline

Grauer & Weil's roadmap rests on surface treatment chemicals and related industrial products, with several business lines supporting earnings.

Revenue grew from Rs 782.11 crore in FY22 to Rs 1,239.78 crore in FY26, a 58.5% rise, and FY26 revenue was 5.1% higher than FY25. FY26 net profit rose 4.3% to Rs 164.03 crore. Over four years, net profit rose from Rs 78.77 crore in FY22 to Rs 164.03 crore. In Q1 FY27, revenue grew 17.0% to Rs 311.11 crore. Operating margin was 18.87% in FY26.

Debt to equity is 0.01 and return on equity is 15.16%. FY26 operating cash flow was Rs 151.86 crore against capital expenditure of Rs 53.65 crore. Grauer & Weil paid a dividend of Rs 1 per share for FY26, a yield of 1.28%. At a P/E of 22.12 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: The P/E of 22.12 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Heritage Foods: Value-Added Dairy Drives the Pipeline

Heritage Foods' roadmap rests on milk, curd and value-added dairy products sold across southern and other states, with branded dairy demand supporting volumes.

Revenue grew from Rs 2,692.55 crore in FY22 to Rs 4,550.22 crore in FY26, a 69.0% rise, and FY26 revenue was 9.3% higher than FY25. FY26 net profit was Rs 150.14 crore. In Q1 FY27, revenue grew 17.7% to Rs 1,344.50 crore. Operating margin was 5.86% in FY26.

Debt to equity is 0.33 and return on equity is 13.61%. FY26 operating cash flow was Rs 237.18 crore against capital expenditure of Rs 382.39 crore. Heritage Foods paid a dividend of Rs 2.5 per share for FY26, a yield of 0.65%. At a P/E of 26.48 against an industry P/E of 34.85, the stock trades below its industry multiple.

What to watch: Net profit margin is only 3.3%, so small cost changes move earnings.

Best Prescription Brand, Surface Treatment Firm and Milk Products Stocks in India: Mankind Pharma vs Grauer & Weil vs Heritage Foods on Key Financials

Among the best prescription brand, surface treatment firm and milk products stocks in India, Mankind Pharma leads on FY26 revenue growth and FY26 operating margin; Grauer & Weil leads on return on equity and the lowest P/E; Heritage Foods leads on Q1 FY27 revenue growth. The table puts the numbers side by side.

Metric	Mankind Pharma	Grauer & Weil	Heritage Foods
FY26 revenue (Rs Cr)	14,636.43	1,239.78	4,550.22
FY26 revenue growth	14.8%	5.1%	9.3%
FY26 net profit (Rs Cr)	1,938.10	164.03	150.14
FY26 operating profit margin	27.06%	18.87%	5.86%
Q1 FY27 revenue growth (YoY)	11.7%	17.0%	17.7%
Return on equity	11.74%	15.16%	13.61%
P/E ratio	47.91	22.12	26.48
Debt to equity	0.39	0.01	0.33
Dividend yield	0.04%	1.28%	0.65%
FY26 operating cash flow (Rs Cr)	3,121.29	151.86	237.18

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Prescription Brand, Surface Treatment Firm and Milk Products Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen prescription brand, surface treatment firm and milk products stocks and shortlist prescription brand, surface treatment firm and milk products stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check revenue growth, operating margin and cash flow together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these prescription brand, surface treatment firm and milk products stocks

Risks to Consider Before Investing in Prescription Brand, Surface Treatment Firm and Milk Products Stocks

Consumer demand: Spending patterns can shift sales between quarters.
Input costs: Changes in raw material prices can affect margins.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Mankind Pharma, Grauer & Weil and Heritage Foods live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover medicines, surface chemicals and dairy. Mankind Pharma leads on FY26 revenue growth and FY26 operating margin; Grauer & Weil leads on return on equity and the lowest P/E; Heritage Foods leads on Q1 FY27 revenue growth.

Across prescription brand, surface treatment firm and milk products stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the prescription brand, surface treatment firm and milk products stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Prescription Brand, Surface Treatment Firm and Milk Products Stocks

Which are the best prescription brand, surface treatment firm and milk products stocks in India with a strong roadmap?

Ans. Mankind Pharma, Grauer & Weil (India) and Heritage Foods stand out for their roadmaps in medicines, surface chemicals and dairy. FY26 revenue growth was 14.8% at Mankind Pharma, 5.1% at Grauer & Weil and 9.3% at Heritage Foods, and return on equity ranges from 11.74% to 15.16%.

Is Mankind Pharma a good stock to buy now?

Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Mankind Pharma, Grauer & Weil and Heritage Foods?

Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 22.12 for Grauer & Weil (industry 36.60) and 26.48 for Heritage Foods (industry 34.85). Only Mankind Pharma trades at or above the industry multiple.

Which of these prescription brand, surface treatment firm and milk products stocks has the highest return on equity?

Ans. Grauer & Weil (India) has the highest return on equity at 15.16%, followed by Heritage Foods at 13.61% and Mankind Pharma at 11.74%.

What are the risks of investing in prescription brand, surface treatment firm and milk products stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Mankind Pharma, Grauer & Weil and Heritage Foods perform in Q1 FY27?

Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Grauer & Weil (India) reported revenue of Rs 311.11 crore, up 17.0% year on year. Heritage Foods reported revenue of Rs 1,344.50 crore, up 17.7% year on year.

Do prescription brand, surface treatment firm and milk products stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 1.28% for Grauer & Weil and 0.65% for Heritage Foods, based on dividends declared for FY26.

How can I invest in prescription brand, surface treatment firm and milk products stocks in India?

Ans. You can buy prescription brand, surface treatment firm and milk products stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.